Today's Rundown Apple and Google launch contact tracing API for COVID-19 exposure Gilead to start selling remdesivir in coming weeks, expects 'multi-year commercial opportunity' It’s too soon to assume success for Moderna’s COVID-19 vaccine: analyst Payers have lowered barriers to telehealth. Will those changes stick? Here's what experts have to say Color gets green light for LAMP-based COVID-19 screening test Biopharma roundup: Roche starts new Actemra trial; Fujifilm's Avigan fails to show efficacy Healthcare roundup: HHS provides $225M for COVID-19 testing at rural clinics Pandemic exposes academic health systems' need to be able to rapidly scale, UPMC and Hopkins docs say Citing a COVID-19 portfolio review—not lawsuits—J&J pulls baby powder from U.S. market Atea raises $215M to support midphase COVID-19 antiviral trial Featured Story | | | Wednesday, May 20, 2020 Apple and Google today rolled out their digital contact tracing technology that can be used by public health agencies to track COVID-19. Find out how the tech giants' collaboration on technology could accelerate the process of tracking and tracing the virus. |
|
|---|
|
Top Stories Wednesday, May 20, 2020 Gilead Sciences’ initial donation of remdesivir will be exhausted by early summer. The biotech will start charging for the drug in COVID-19 after that, and it could become a "multi-year commercial opportunity" rather than just a year or two of revenue flow, Gilead CFO Andrew Dickinson told an analyst. Wednesday, May 20, 2020 Evercore ISI analyst Umer Raffat analyzed the data Moderna released earlier this week on its experimental COVID-19 mRNA vaccine and found some shortcomings that he believes the company will have to address in phase 3 trials. They include questions about the validity of comparators the company used and the durability of protection the vaccine offers. Wednesday, May 20, 2020 In response to the COVID-19 pandemic, the Trump administration has opened up access to telehealth with sweeping, but temporary, changes to reimbursement policies. Will any of these changes remain permanent or will reimbursement policies roll back to pre-COVID levels? Find out what experts have to say. Wednesday, May 20, 2020 Genomic testing firm Color received an emergency authorization from the FDA for its scalable COVID-19 screening method, which differs from the standard PCR-based technologies widely used so far. Wednesday, May 20, 2020 Roche's Genentech has launched a new study of Actemra in COVID-19 to focus on underserved and minority populations. Fujifilm's flu drug Avigan has reportedly showed no efficacy in tests among mild and asymptomatic patients. Wednesday, May 20, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Wednesday, May 20, 2020 The current pandemic exposed academic health systems' need to be able to rapidly scale capacity. Wednesday, May 20, 2020 Johnson & Johnson says it's pulling its talc-based powders from the U.S. and Canadian markets. But the move comes as the drugmaker faces thousands of personal injury lawsuits over the product's safety—and as demand has fallen due to years of publicity about the legal fight. Wednesday, May 20, 2020 Bain Capital Life Sciences has powered Atea Pharmaceuticals to a $215 million financing round. The series D sets Atea up to run a phase 2 trial of its oral purine nucleotide prodrug in people hospitalized with moderate cases of COVID-19. |
